Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ULURU, a specialty pharmaceutical company, has received a marketing approval for Altrazeal in New Zealand.
Subscribe to our email newsletter
The company expects to launch Altrazeal in six additional markets for human and veterinary use, in the near future.
The company also expects to receive approval in the second quarter of 2012 from SFDA, the regulatory body for China.
ULURU president and CEO Kerry Gray said to support the launch of Altrazeal in Australia and New Zealand a five center, 60 patient study, has been initiated in Australia.
"A second 90 patient comparative study is planned to be conducted in Europe. This study is to support reimbursement submissions by demonstrating pharmacoeconomic benefits," Gray added.